{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:26:41Z","timestamp":1786973201654,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005156","name":"Alexander von Humboldt-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61486-7","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:15:59Z","timestamp":1784304959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD25 genetic ablation on lymphoid cell lines to obtain models of stimulation through the Interleukin-2 beta\/gamma receptor"],"prefix":"10.1038","volume":"16","author":[{"given":"Ernesto","family":"Relova-Hern\u00e1ndez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Beatriz","family":"D\u00edaz-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arleen","family":"Cantero-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rydell","family":"Alvarez-Arzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayeli","family":"Hern\u00e1ndez-\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Carmenate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertrudis","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"61486_CR1","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman, O. & Sprent, J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 12, 180\u2013190. https:\/\/doi.org\/10.1038\/nri3156 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"61486_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00000658-199809000-00004","volume":"228","author":"SA Rosenberg","year":"1998","unstructured":"Rosenberg, S. A., Yang, J. C., White, D. E. & Steinberg, S. M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 228, 307\u2013319. https:\/\/doi.org\/10.1097\/00000658-199809000-00004 (1998).","journal-title":"Ann. Surg."},{"key":"61486_CR3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1200\/JCO.1991.9.4.694","volume":"9","author":"JP Siegel","year":"1991","unstructured":"Siegel, J. P. & Puri, R. K. Interleukin-2 toxicity. J. Clin. Oncol. 9, 694\u2013704. https:\/\/doi.org\/10.1200\/JCO.1991.9.4.694 (1991).","journal-title":"J. Clin. Oncol."},{"key":"61486_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.2005.03.6830","volume":"24","author":"GC Cesana","year":"2006","unstructured":"Cesana, G. C. et al. Characterization of CD4\u2009+\u2009CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J. Clin. Oncol. 24, 1169\u20131177. https:\/\/doi.org\/10.1200\/JCO.2005.03.6830 (2006).","journal-title":"J. Clin. Oncol."},{"key":"61486_CR5","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","volume":"365","author":"J Koreth","year":"2011","unstructured":"Koreth, J. et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl. J. Med. 365, 2055\u20132066. https:\/\/doi.org\/10.1056\/NEJMoa1108188 (2011).","journal-title":"N Engl. J. Med."},{"key":"61486_CR6","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","volume":"1","author":"A Hartemann","year":"2013","unstructured":"Hartemann, A. et al. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 1, 295\u2013305. https:\/\/doi.org\/10.1016\/S2213-8587(13)70113-X (2013).","journal-title":"Lancet Diabetes Endocrinol"},{"key":"61486_CR7","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.immuni.2010.08.004","volume":"33","author":"TR Malek","year":"2010","unstructured":"Malek, T. R. & Castro, I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33, 153\u2013165. https:\/\/doi.org\/10.1016\/j.immuni.2010.08.004 (2010).","journal-title":"Immunity"},{"key":"61486_CR8","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/ITT.S500229","volume":"14","author":"A Dashwood","year":"2025","unstructured":"Dashwood, A., Ghodsinia, A. A., Dooley, J. & Liston, A. Cytokine couture: designer IL2 molecules for the treatment of disease. Immunotargets Ther. 14, 403\u2013431. https:\/\/doi.org\/10.2147\/ITT.S500229 (2025).","journal-title":"Immunotargets Ther."},{"key":"61486_CR9","doi-asserted-by":"publisher","first-page":"6230","DOI":"10.4049\/jimmunol.1201895","volume":"190","author":"T Carmenate","year":"2013","unstructured":"Carmenate, T. et al. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J. Immunol. 190, 6230\u20136238. https:\/\/doi.org\/10.4049\/jimmunol.1201895 (2013).","journal-title":"J. Immunol."},{"key":"61486_CR10","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/2326-6066.CIR-15-0195","volume":"4","author":"GC Sim","year":"2016","unstructured":"Sim, G. C. et al. IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation. Cancer Immunol. Res. 4, 983\u2013994. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0195 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"61486_CR11","doi-asserted-by":"publisher","first-page":"e1277306","DOI":"10.1080\/2162402X.2016.1277306","volume":"6","author":"C Klein","year":"2016","unstructured":"Klein, C. et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines. Oncoimmunology 6, e1277306. https:\/\/doi.org\/10.1080\/2162402X.2016.1277306 (2016).","journal-title":"Oncoimmunology"},{"key":"61486_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/s41419-018-1047-2","volume":"9","author":"X Chen","year":"2018","unstructured":"Chen, X. et al. A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2. Cell. Death Dis. 9, 989. https:\/\/doi.org\/10.1038\/s41419-018-1047-2 (2018).","journal-title":"Cell. Death Dis."},{"key":"61486_CR13","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1038\/s41598-022-09278-7","volume":"12","author":"R Dehghan","year":"2022","unstructured":"Dehghan, R. et al. Efficacy and antitumor activity of a mutant type of interleukin 2. Sci. Rep. 12, 5376. https:\/\/doi.org\/10.1038\/s41598-022-09278-7 (2022).","journal-title":"Sci. Rep."},{"key":"61486_CR14","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nature10975","volume":"484","author":"AM Levin","year":"2012","unstructured":"Levin, A. M. et al. Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019. Nature 484, 529\u2013533. https:\/\/doi.org\/10.1038\/nature10975 (2012).","journal-title":"Nature"},{"key":"61486_CR15","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/s42003-023-05188-0","volume":"6","author":"G Rojas","year":"2023","unstructured":"Rojas, G. et al. Molecular reshaping of phage-displayed Interleukin-2 at beta chain receptor interface to obtain potent super-agonists with improved developability profiles. Commun. Biol. 6, 828. https:\/\/doi.org\/10.1038\/s42003-023-05188-0 (2023).","journal-title":"Commun. Biol."},{"key":"61486_CR16","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.immuni.2015.04.018","volume":"42","author":"S Mitra","year":"2015","unstructured":"Mitra, S. et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 42, 826\u2013838. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.018 (2015).","journal-title":"Immunity"},{"key":"61486_CR17","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.4049\/jimmunol.1700433","volume":"200","author":"T Carmenate","year":"2018","unstructured":"Carmenate, T. et al. Blocking IL-2 signal in vivo with an IL-2 antagonist reduces tumor growth through the control of regulatory T cells. J. Immunol. 200, 3475\u20133484. https:\/\/doi.org\/10.4049\/jimmunol.1700433 (2018).","journal-title":"J. Immunol."},{"key":"61486_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41586-021-03861-0","volume":"597","author":"F Mo","year":"2021","unstructured":"Mo, F. et al. An engineered IL-2 partial agonist promotes CD8\u2009+\u2009T cell stemness. Nature 597, 544\u2013548. https:\/\/doi.org\/10.1038\/s41586-021-03861-0 (2021).","journal-title":"Nature"},{"key":"61486_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/268154a0","volume":"268","author":"S Gillis","year":"1977","unstructured":"Gillis, S. & Smith, K. A. Long term culture of tumour-specific cytotoxic T cells. Nature 268, 154\u2013156. https:\/\/doi.org\/10.1038\/268154a0 (1977).","journal-title":"Nature"},{"key":"61486_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1182\/blood.V70.4.1069.1069","volume":"70","author":"T Hori","year":"1987","unstructured":"Hori, T. et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia\/lymphoma virus. Blood 70, 1069\u20131072 (1987).","journal-title":"Blood"},{"key":"61486_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.immuni.2009.11.010","volume":"32","author":"V Kalia","year":"2010","unstructured":"Kalia, V. et al. Prolonged interleukin-2R alpha expression on virus-specific CD8\u2009+\u2009T cells favors terminal-effector differentiation in vivo. Immunity 32, 91\u2013103. https:\/\/doi.org\/10.1016\/j.immuni.2009.11.010 (2010).","journal-title":"Immunity"},{"key":"61486_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41586-022-05257-0","volume":"610","author":"M Hashimoto","year":"2022","unstructured":"Hashimoto, M. et al. PD-1 combination therapy with IL-2 modifies CD8\u2009+\u2009T cell exhaustion program. Nature 610, 173\u2013181. https:\/\/doi.org\/10.1038\/s41586-022-05257-0 (2022).","journal-title":"Nature"},{"key":"61486_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jbiotec.2024.07.013","volume":"393","author":"SL Lozada","year":"2024","unstructured":"Lozada, S. L. et al. Oxidative refolding by copper-catalyzed air oxidation consistently increases the homogeneity and activity of a novel Interleukin-2 mutein. J. Biotechnol. 393, 81\u201390. https:\/\/doi.org\/10.1016\/j.jbiotec.2024.07.013 (2024).","journal-title":"J. Biotechnol."},{"key":"61486_CR24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/jmr.2440","volume":"28","author":"G Rojas","year":"2015","unstructured":"Rojas, G., Carmenate, T. & Leon, K. Molecular dissection of the interactions of an antitumor interleukin-2-derived mutein on a phage display-based platform. J. Mol. Recognit. 28, 261\u2013268. https:\/\/doi.org\/10.1002\/jmr.2440 (2015).","journal-title":"J. Mol. Recognit."},{"key":"61486_CR25","doi-asserted-by":"publisher","first-page":"15373","DOI":"10.1038\/ncomms15373","volume":"8","author":"R Vazquez-Lombardi","year":"2017","unstructured":"Vazquez-Lombardi, R. et al. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells. Nat. Commun. 8, 15373. https:\/\/doi.org\/10.1038\/ncomms15373 (2017).","journal-title":"Nat. Commun."},{"key":"61486_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41598-018-37280-5","volume":"9","author":"G Rojas","year":"2019","unstructured":"Rojas, G. et al. Directed evolution of super-secreted variants from phage-displayed human Interleukin-2. Sci. Rep. 9, 800. https:\/\/doi.org\/10.1038\/s41598-018-37280-5 (2019).","journal-title":"Sci. Rep."},{"key":"61486_CR27","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.4049\/jimmunol.120.6.2027","volume":"120","author":"S Gillis","year":"1978","unstructured":"Gillis, S., Ferm, M. M., Ou, W. & Smith, K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J. Immunol. 120, 2027\u20132032. https:\/\/doi.org\/10.4049\/jimmunol.120.6.2027 (1978).","journal-title":"J. Immunol."},{"key":"61486_CR28","doi-asserted-by":"publisher","first-page":"vkaf208","DOI":"10.1093\/jimmun\/vkaf208","volume":"28","author":"E Relova-Hern\u00e1ndez","year":"2025","unstructured":"Relova-Hern\u00e1ndez, E. et al. Enhanced affinity for the IL-2 receptor \u03b2 subunit potently increases antitumor efficacy of IL-2 across various tumor models by reshaping the tumor microenvironment. J. Immunol. 28, vkaf208. https:\/\/doi.org\/10.1093\/jimmun\/vkaf208 (2025).","journal-title":"J. Immunol."},{"key":"61486_CR29","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/pro.3519","volume":"27","author":"R Morris","year":"2018","unstructured":"Morris, R., Kershaw, N. J. & Babon, J. J. The molecular details of cytokine signaling via the JAK\/STAT pathway. Protein Sci. 27, 1984\u20132009. https:\/\/doi.org\/10.1002\/pro.3519 (2018).","journal-title":"Protein Sci."},{"key":"61486_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2013.07.012","volume":"397","author":"M Wadhwa","year":"2013","unstructured":"Wadhwa, M., Bird, C., Heath, A. B., Dilger, P. & Thorpe, R. participants of the collaborative study. The 2nd International Standard for Interleukin-2 (IL-2). Report of a collaborative study. J. Immunol. Methods. 397, 1\u20137. https:\/\/doi.org\/10.1016\/j.jim.2013.07.012 (2013).","journal-title":"J. Immunol. Methods"},{"key":"61486_CR31","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1084\/jem.150.6.1510","volume":"150","author":"J Watson","year":"1979","unstructured":"Watson, J. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J. Exp. Med. 150, 1510\u20131519. https:\/\/doi.org\/10.1084\/jem.150.6.1510 (1979).","journal-title":"J. Exp. Med."},{"key":"61486_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ijc.2910190505","volume":"19","author":"U Schneider","year":"1977","unstructured":"Schneider, U., Schwenk, H. U. & Bornkamm, G. Characterization of EBV-genome negative null and T cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma. Int. J. Cancer. 19, 621\u2013626. https:\/\/doi.org\/10.1002\/ijc.2910190505 (1977).","journal-title":"Int. J. Cancer"},{"key":"61486_CR33","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.4049\/jimmunol.134.3.1623","volume":"134","author":"J Yodoi","year":"1985","unstructured":"Yodoi, J. et al. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells). J. Immunol. 134, 1623\u20131630 (1985).","journal-title":"J. Immunol."},{"key":"61486_CR34","doi-asserted-by":"publisher","first-page":"112902","DOI":"10.1016\/j.jim.2020.112902","volume":"487","author":"G Pfister","year":"2020","unstructured":"Pfister, G., Toor, S. M., Sasidharan Nair, V. & Elkord, E. An evaluation of sorter induced cell stress (SICS) on peripheral blood mononuclear cells (PBMCs) after different sort conditions - Are your sorted cells getting SICS? J. Immunol. Methods. 487, 112902. https:\/\/doi.org\/10.1016\/j.jim.2020.112902 (2020).","journal-title":"J. Immunol. Methods"},{"key":"61486_CR35","doi-asserted-by":"publisher","unstructured":"Burnett, L. C., Lunn, G. & Coico, R. Biosafety: guidelines for working with pathogenic and infectious microorganisms. Curr Protoc. Microbiol. Suppl. 13 https:\/\/doi.org\/10.1002\/9780471729259.mc01a01s13 (2009). 1A.1.1-1A.1.14.","DOI":"10.1002\/9780471729259.mc01a01s13"},{"key":"61486_CR36","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","volume":"160","author":"P Brodin","year":"2015","unstructured":"Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37\u201347. https:\/\/doi.org\/10.1016\/j.cell.2014.12.020 (2015).","journal-title":"Cell"},{"key":"61486_CR37","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1158\/2326-6066.CIR-21-0831","volume":"10","author":"CJ Nirschl","year":"2022","unstructured":"Nirschl, C. J. et al. Discovery of a conditionally activated IL-2 that promotes antitumor immunity and induces tumor regression. Cancer Immunol. Res. 10, 581\u2013596. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0831 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"61486_CR38","doi-asserted-by":"publisher","unstructured":"Richardson, J. H., Sodroski, J. G., Waldmann, T. A. & Marasco, W. A. Phenotypic knockout of the high-affinity human interleukin 2 receptor by intracellular single-chain antibodies against the alpha subunit of the receptor. Proc. Natl. Acad. Sci USA. 92, 3137\u20133141; (1995). https:\/\/doi.org\/10.1073\/pnas.92.8.3137 (1995).","DOI":"10.1073\/pnas.92.8.3137"},{"key":"61486_CR39","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.4049\/jimmunol.161.10.5430","volume":"161","author":"DM Eicher","year":"1998","unstructured":"Eicher, D. M. & Waldmann, T. A. IL-2R alpha on one cell can present IL-2 to IL-2R beta\/gamma(c) on another cell to augment IL-2 signaling. J. Immunol. 161, 5430\u20135437 (1998).","journal-title":"J. Immunol."},{"key":"61486_CR40","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1126\/science.1225829","volume":"337","author":"M Jinek","year":"2012","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816\u2013821. https:\/\/doi.org\/10.1126\/science.1225829 (2012).","journal-title":"Science"},{"key":"61486_CR41","doi-asserted-by":"publisher","first-page":"e65777","DOI":"10.7554\/eLife.65777","volume":"10","author":"CR Glassman","year":"2021","unstructured":"Glassman, C. R. et al. Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. Elife 10, e65777. https:\/\/doi.org\/10.7554\/eLife.65777 (2021).","journal-title":"Elife"},{"key":"61486_CR42","doi-asserted-by":"publisher","first-page":"589042","DOI":"10.3389\/fimmu.2025.1589042","volume":"16","author":"A Caballero","year":"2025","unstructured":"Caballero, A. et al. First-in-human evaluation of a no-alpha interleukin-2 mutein: safety and preliminary pharmacodynamic and clinical effect. Front. Immunol. 16, 589042. https:\/\/doi.org\/10.3389\/fimmu.2025.1589042 (2025).","journal-title":"Front. Immunol."},{"key":"61486_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s10059-000-0575-6","volume":"10","author":"K Kwack","year":"2000","unstructured":"Kwack, K. & Lynch, R. G. A new non-radioactive method for IL-2 bioassay. Mol. Cells. 10, 575\u2013578. https:\/\/doi.org\/10.1007\/s10059-000-0575-6 (2000).","journal-title":"Mol. Cells"},{"key":"61486_CR44","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1472-6750-13-52","volume":"13","author":"V J\u00e4ger","year":"2013","unstructured":"J\u00e4ger, V. et al. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol. 13, 52. https:\/\/doi.org\/10.1186\/1472-6750-13-52 (2013).","journal-title":"BMC Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61486-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61486-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61486-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:49:20Z","timestamp":1786970960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61486-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61486"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61486-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25705"}}